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Introduction: Castleman’s disease (CD), first described by Benjamin Castleman in 1954, is a 
giant or angiofollicular lymph node hyperplasia, described as a rare monotypic polyclonal B-cell 
lymphoproliferative disorder with an incompletely understood pathogenesis and variable clinical 
behavior. This study aimed to determine the incidence of CD diagnosis over an 11-year period. Addi-
tionally, the study aimed to describe the demographic, laboratory, and pathological features of CD.
Methods: This is a retrospective study where the demographic and laboratory data were retrieved 
from the Tygerberg Academic Hospital (TAH) patient electronic records and Tygerberg Lym-
phoma Study Group (TLSG) and statistical analysis performed on the patients diagnosed with CD.
Results: Fifty-four patients were diagnosed with CD during this period. The median age at 
presentation was 39 years (range: 9–58). HIV serology was available in 53 patients, of which 
51 were HIV-positive and two were HIV-negative. The history of initiation of antiretroviral 
therapy at diagnosis was available in 43 patients (38 on treatment, four were not on treatment, 
and one defaulted treatment). The median CD4 count was 232.50 cells/μL (range: 2–883). The 
HIV viral load was performed in 43 patients at diagnosis, which was <49 HIV-1 RNA copies/
μL in more than half of the patients (58%). Diagnosis was made on lymph node biopsies in 53 
patients, with one case diagnosed on a spleen biopsy. Kaposi sarcoma was found on the same 
tissue biopsy in 13 cases. A bone marrow biopsy was performed in 31 patients. The predominant 
features noted were a disorganized hypercellular marrow with plasmocytosis.
Conclusion: CD is a rare polyclonal B-cell lymphoproliferative disorder. However, we dem-
onstrated a significant increase in the incidence of HIV-associated multicentric CD over the last 
decade in our area in South Africa.
Keywords: Castleman’s disease, HIV-endemic setting, HHV-8 status, CD4 count, clinico-
pathological correlation
Introduction
Castleman’s disease (CD), also known as giant or angiofollicular lymph node hyper-
plasia, is a rare monotypic polyclonal B-cell lymphoproliferative disorder with an 
incompletely understood pathogenesis and variable clinical behavior. The disease 
likely encompasses several clinical and pathological entities with overlapping features. 
It was first described in 1954 by Benjamin Castleman, a pathologist who reported 
a patient presented with fever and weakness with mediastinal lymphadenopathy.1 
The histological features were so distinctive that they were later characterized as the 
typical hyaline vascular variant of CD.1 In 1972, several cases with novel histologic 
characteristics were diagnosed and called plasma cell variant.2 CD has been classi-
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fied clinically according to the extent of lymphadenopathy 
into unicentric Castleman’s disease (UCD) and multicentric 
Castleman’s disease (MCD). UCD cases mostly show hyaline 
vascular variant histology, while the plasma cell variant is 
less commonly encountered. The majority of the MCD cases 
have plasma cell variant histology especially in the setting 
of HIV infection.3,4 The rarity of the disease and its clinical–
pathological heterogeneity have precluded comprehensive 
studies to be conducted, and the current knowledge is based 
mainly on retrospective case series studies and histological 
reviews. MCD is a rare disease with an increasing prevalence 
on HIV-infected individuals. South Africa has the largest HIV 
epidemic in the world, with an estimated 7 million people 
living with HIV in 2015, hence the rationale for studying the 
incidence of this disease in this setting.5–7 To the best of our 
knowledge, there are very limited data from South Africa and 
the African continent regarding the epidemiology of CD. We 
conducted a thorough literature search for similar studies in 
South Africa and the African content. The only study that we 
found is a descriptive retrospective study conducted at Chris 
Hani Baragwanath Academic Hospital (CHBAH), Johannes-
burg, South Africa, over a 25-year period (1990–2014).8 On 
the African landscape, however, only isolated case reports 
have been published. Thus, we anticipate that this study 
will shed some light on the epidemiology of CD in the HIV-
endemic setting and may direct the way in how we approach 
the diagnosis and staging using bone marrow biopsy of this 
condition. CD comprises different subtypes, with different 
prognoses. Both unicentric and multicentric have specific 
systemic manifestations and could be associated with Kaposi 
sarcoma (KS), Hodgkin’s or non-Hodgkin’s lymphomas, as 
well as POEMS syndrome. The cause and pathogenesis of CD 
can be split into three main subtypes namely UCD, idiopathic 
MCD, and human herpesvirus-8-associated MCD (HHV8+ 
MCD). In our case series, we focus on HHV8+ MCD.
The main aim of the study is to bring a new highlight in the 
landscape of viral infections and CD. It assesses the incidence 
of CD diagnosed at Tygerberg Academic Hospital (TAH) over 
an 11-year period. Additionally, the study aims to describe the 
demographic, laboratory, and pathological features of CD cases 
diagnosed at TAH during the same period. The objectives of 
the research were to correlate various histological variants of 
CD in relation to the HIV status and document the human 
herpesvirus-8 (HHV8) (latency-associated nuclear antigen 
[LANA]) immunohistochemistry (IHC) result on the tissue 
biopsy. Secondary objectives were to determine the frequency 
of codiagnosis of KS in relation to the CD4 count of the patient, 
as well as to document the marrow involvement and bone mar-
row histological and IHC features of CD in order to highlight 
how bone marrow assessment in such cases should be made.
Methods
study population
This study is a retrospective observational study, which is 
part of a larger study under the Tygerberg Lymphoma Study 
Group (TLSG) at Tygerberg Hospital that was started in 2007 
and its ethical approval number is HREC No: N07/03/068. 
Thus, it is a retrospective descriptive study of CD cases 
diagnosed in the Division of Anatomical Pathology and 
Division of Haematopathology, Department of Pathology, 
National Health Laboratory Service (NHLS), TAH during the 
period January 2007 to December 2017. Data for the study 
were extracted from Tygerberg Hospital patient electronic 
records of investigations through Disa laboratory (Disalab 
version 04.16.04.373) and TrakCare IT systems using the 
key word “Castleman disease.” The database of the TLSG 
was also used for CD data collection. The data obtained 
were carefully reviewed to avoid duplication and to apply 
the inclusion and exclusion criteria. All data were collected 
on Microsoft Excel® spread sheet and submitted for analysis 
to the statistician.
inclusion and exclusion criteria
All patients newly diagnosed with CD by tissue biopsy 
and confirmed by IHC stains in the Division of Anatomical 
Pathology, NHLS - Tygerberg Hospital as well as the Division 
of Hematology were included. The exclusion criteria refer to 
all patients diagnosed with relapsed CD, as well to all patients 
who had a lymph node histological feature suggestive of CD, 
but not confirmed by IHC.
Data analysis
Categorical data were described using charts and expressed 
in proportions and percentages. The continuous data were 
described using mean and SD if normally distributed; how-
ever, median and range were used to describe continuous data 
if the distribution is skewed. The chi-squared test was used 
to compare categorical variables between the groups while 
independent t-test used for normally distributed continuous 
variable and Mann–Whitney test for continuous variables 
with skewed distribution, as previously described.9–12
Results
Demographics
Data were obtained from 54 patients who were diagnosed 
with CD on tissue biopsy from January 2007 to December 
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2017 in the Department of Anatomical Pathology, National 
Health Laboratory Service-TAH. Out of the 54 cases diag-
nosed with CD, there were two (3.7%) HIV-negative cases, 
51 (94.4%) HIV-positive cases, and in a single case the HIV 
status was unknown. There was an increasing trend in the 
number of HIV-associated MCD with a peak of 13 cases 
diagnosed in 2015, the number of cases declined slightly in 
2016 to nine cases, however in general cases have steadily 
increased since 2007. The mean age at diagnosis was 38.15 
years, the age range was 9–58 years, and median age was 
39 years. Only one patient was diagnosed with CD in the 
first decade of life. There were six (11.1%) cases that were 
diagnosed in the third decade of life (20–29 years), 20 (37%) 
cases in the fourth decade of life (30–39 years), 21 (38.9%) 
cases in the fifth decade of life (40–49 years), and six (11.1%) 
cases in the sixth decade of life (50–59 years). There were 27 
(50%) male patients and 27 (50%) female patients. Our find-
ings showed an equal male to female ratio (Figures S1–S5).
CD4 count and hiV viral load (Vl)
In our cohort, 51 (94.4%) patients were HIV-positive, only 
two (3.7%) patients were HIV-negative, and in one patient the 
HIV status was unknown (1.9%). Out of the 51 HIV-positive 
patients, 38 (74.5%) patients were on antiretroviral therapy 
(ART) at the time of diagnosis, four (7.9%) patients were not 
on treatment, one (1.9%) patient defaulted treatment, and in 
eight (15.7%) patients the treatment history was unknown. 
The treatment history of the patients was obtained from the 
histological reports.
Forty-eight (94.1%) of the HIV-positive patients had 
their CD4 counts performed at the time of diagnosis and 
in three (5.9%) of the HIV-positive patients the CD4 count 
was unknown. The median CD4 count was 232.50 cell/μL 
(range: 2–883 cells/μL). In 42% of the patients, the CD4 
count was <200 cells/μL, while in 29% of the patients the 
CD4 counts were between 200 and 350 cells/μL. The CD4 
counts ranged between 351 and 500 cells/μL in 14% of the 
patients and >500 cells/μL in 15% of the patients at the onset 
of diagnosis (Figure 1).
HIV VLs showed significant variability between patients; 
however, many patients had very low or undetectable VLs. 
Forty-three of the HIV-positive patients had their VLs mea-
sured around the time of diagnosis of CD. More than half 
of the patients (58%) had VL <49 RNA copies/μL. Only 
one patient (2%) had a VL between 50 and 99 RNA copies/
μL. The VL was between 100 and 1,000 RNA copies/μL in 
five patients (12%) and 12 (28%) patients had a VL >1,000 
RNA copies/μL. Out of the 12 patients with a VL >1,000 
RNA copies/μL, four patients were on ART, one not on ART, 
one defaulted ART, and in six patients the ART history was 
unknown (Figure 2).
histology of CD
The diagnosis of CD was made on a lymph node biopsy in 
total n=53 (98.1%) patients, with only one patient (1.8%) 
being diagnosed on splenic tissue. The diagnosis of CD on 
tissue biopsies was made by two independent anatomical 
pathologists. Histological variants were reported in 37 (37/54) 
(68.5%) patients diagnosed with CD. The hyaline vascular 
variant was reported in the two HIV-negative patients. In HIV-
associated MCD, plasma cell variant was the most common 
variant reported in 20/35 (57%) patients followed by mixed 
variant (23%). The hyaline vascular variant was reported in 
17% of the cases and only one (3%) case was reported as 
plasmablastic variant (Figure 3). A characteristic histologi-
cal finding is that the plasmablasts are all IgM lambda but 
polyclonal.
The coexistence of KS was seen in 13 (24.1%) cases, 
and all the cases were HIV-positive. When compared with 
the group of patients with only CD on tissue biopsy (41/54), 
the cohort of patients with coexisting KS (13/54) was asso-
ciated with a younger median age at presentation (33.31 vs 
39.68 years, P=0.036), lower median platelet count (57 vs 
199.5×109/L, P=0.006), and CD4 count <200 cells/μL (66.7% 
vs 33.3%, P=0.042) (Tables 1 and 2). HHV8 (LANA-1) IHC 
stain was requested in 52 of the cases and it was positive in 
49 (94.2%) of the cases, while it was negative in three (5.8%) 
of the cases. In the 49 cases with HHV8 infection, 47 cases 
were HIV-positive, one patient was HIV-negative, and in a 
Figure 1 CD4 counts of the patients included in the study.
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single case the HIV status was unknown. In the three cases 
where HHV8 was negative, one was HIV-negative and two 
were HIV-positive cases (Figure 4).
Bone marrow biopsy of CD
Thirty-one (31/54) patients diagnosed with CD had bone 
marrow biopsy procedures performed at the time of diagno-
sis. Plasmocytosis was found in 25/31 (80.6%) patients who 
underwent bone marrow biopsies, hypercellularity was found 
Figure 2 Viral load of the patients included in the study.
Abbreviations: hhV, human herpesvirus; ihC, immunohistochemistry.
Figure 3 histological subtypes of the patients included in the study. 
Abbreviations: MCD, multicentric Castleman’s disease; PCV, plasma cell variant; 
PBV, Patent blue V; hVV, hyaline vasculare variant; MV, multicentric varian.
in 22/31 (71%), and the bone marrow architecture was disor-
ganized in 14/31 (45.2%) of the cases. Lymphoid aggregates 
were detected in 11/31 (35.5%) of the cases. CD-like follicles 
were detected in 5/31 (16.1%) of the cases and granulomas 
were detected in only one case. Histologic features suggestive 
of bone marrow infiltration by KS were reported in one case. 
HHV8 (LANA-1) IHC stain was requested in only 10 cases 
and was found to be positive in 2/10 (20%) cases, while it 
was negative in the rest of the cases.
Discussion
Our article describes 54 patients newly diagnosed with CD 
over an 11-year period from January 2007 to December 2017. 
Almost all the diagnoses were made on lymph node biopsies 
with one exception of a case diagnosed on a splenectomy 
specimen. An increasing trend of incidence of diagnosis of 
CD in an HIV-endemic setting was reported by Abayomi 
et al, who had published preliminary findings of the TLSG 
where they reported only four cases of CD over 8 years 
(2002–2009).5 In comparison, the presently described data 
show a significant increase in the incidence of diagnoses of 
CD in an HIV-endemic setting, with 50 cases diagnosed over 
the subsequent 7 years (2010–2017). A retrospective study 
conducted at Chris Hani Baragwanath Academic Hospital 
(CHBAH) in Johannesburg, South Africa, over a 25-year 
period (1990–2014) identified 38 patients diagnosed with CD. 
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It was reported that 57.9% of MCD cases were diagnosed in 
the last 5 years of the study.13 This study together with our 
findings shows an increase in the incidence of diagnosis of 
MCD in the HIV-endemic setting of South Africa in the last 
decade. Even if we did not include clinical features in our 
study to confidently classify our cases into UCD and MCD, 
Table 1 laboratory data at the time of diagnosis of CD (or the earliest available after diagnosis)
Descriptive statistics
Parameter No Mean Median Minimum Maximum SD
WCC (109/l) 51 n/a 6.31 1.53 16.4 3.33206
hb (g/dl) 51 n/a 7.3 4.1 14 2.26144
MCV (fl) 51 90.72 89.2 73.1 112.2 8.82017
MCh (pg) 51 29.25 28.4 23.1 36.1 3.1604
Platelets (109/l) 51 n/a 172 8 533 134.40245
lDh (μ/l) 40 n/a 335 119 1,530 358.41399
CRP (mg/l) 35 129.78 112 8 346 80.4496
albumin (g/l) 36 22.53 21.5 10 44 7.161
sodium (mmol/l) 49 132.92 133 120 151 5.57089
Ferritin (μg/l) 30 n/a 1,500 65 7,863 2101.80152
Abbreviations: CD, Castleman disease; CRP, C reactive protein; lDh, lactate dehydrogenase; MCh, mean corpuscular hemoglobin; MCV, mean corpuscular volume; 
WCC, white cell count; n/a, not available.
Table 2 Comparison of patients with coexistence Ks on same tissue with CD patients
Characteristics Cases with CD  
histology
(N)=41
Cases with CD  
and KS histology
(N)=13
P-value Total cohort
age, years: median (range) 39.68 (9–58) 33.31 (20–46) 0.036 39 (9–58)
gender
Male 20 7 27
Female 21 6 27
Male:female ratio 0.9:1 1.2:1 1:1
hiV serology
Positive, n (%) 38 (95) 13 (100) 51 (96.2)
negative, n (%) 2 0 2 (3.8)
Viral load Rna copies/μl
<100, n (%) 22 (63.9) 4 (50) 26 (60.5)
100–1,000, n (%) 5 (14.3) 0 5 (11.6)
>1,000, n (%) 8 (22.8) 4 (50) 12 (27.9)
CD4 count cells/μl
Median (range) 279 (89–883) 172.5 (2–500) 232 (2–883)
<200, n (%) 12 (33.3) 8 (66.7) 0.042 20 (41.7)
>200, n (%) 24 (66.7) 4 (33.3) 0.042 28 (58.3)
histology
PCV, n (%) 11 (44) 9 (75) 20 (54.1)
hVV, n (%) 5 (20) 3 (25) 8 (21.6)
MV, n (%) 8 (32) 0 8 (21.6)
PBV, n (%) 1 (4) 0 1 (2.7)
hhV8
Positive, n (%) 36 (94.7) 13 (100) 49 (96.1)
negative, n (%) 2 (5.3) 0 2 (3.9)
FBC
Median WCC, ×109/l (range) 6.31 (1.53–16.4)
Median hb, ×109/l (range) 7.7 (4.1–14) 6.5 (4.5–9.5) 0.050 7.3 (4.1–14)
Median platelet, ×109/l (range) 199.5 (19–533) 57 (8–289) 0.006 172 (8–533)
lDh, μ/l, median (range) 307 (119–1530) 393 (210–1488) 335 (119–1530)
CRP, mg/l, median (range) 120.5 (8–346) 102.8 (64–200) 112 (8–346)
albumin, g/l, median (range) 23.5 (10–44) 19.5 (13–26) 21.5 (10–44)
Ferritin, μg/l, median (range) 1,035 (65.9–7,124) 1,962 (1,500–7,863) 1,500 (65–7,863)
sodium, mmol/l, median (range) 134 (124–142) 132 (120–151) 133 (120–151)
Abbreviations: CD, Castleman disease; Ks, Kaposi sarcoma; hhV, human herpesvirus; CRP, C reactive protein; FBC, full blood count; lDh, lactate dehydrogenase; MV, 
mean value; hVV, hyaline vascular variant; PBV, plasma cell variant; WCC, white cell count.
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HIV infection has been associated with MCD (71.4%) vs 
UCD (1.7%), according to a large single institution retrospec-
tive study.14 In our study, 94.4% of the patients were HIV 
seropositive. We think there are multiple possible causes 
behind this significant and steady increase in the incidence of 
diagnosing HHV8-associated MCD in HIV-positive patients 
at our center. First, there has been an increase in the preva-
lence of HIV in South Africa from 10.6% in 2008 to 18.2% 
in 2014. Second, South Africa launched its ATR program in 
2004 with an increasing ART HIV population coverage each 
year.15–17 This might have resulted in improved survival and 
decreased death rates in HIV people from other causes like 
opportunistic infections. Third, emigration of people from 
other provinces and the continent of Africa to the Western 
Cape might contribute to the trend of increasing incidence 
of this rare disease.
The overall median age at diagnosis in our cohort was 
39 years with a mean of 38.1 years (range: 9–58 years) and 
a male to female ratio of 1:1. These findings are similar 
to those found in the study conducted at CHBAH, where 
the median age was 36 years and mean was 37 years at the 
time of diagnosis with a male to female ratio of 1.2:1. The 
median age at presentation of HIV-associated MCD in South 
Africa appears to be compatible with the high prevalence 
of HIV infection among the 30- to 40-year age group, and 
it is slightly lower in contrast to retrospective studies from 
France, UK, or Australia (median: 41.4, 42, and 43 years), 
respectively.15,18,19 A male predominance was observed in 
the largest single institution case series to date and in one 
systematic review, whereas in our series the incidence was 
equal in men and women.20,21
In our case series, most patients diagnosed with CD 
were HIV-positive, ie, 51/54 (94.4%), two patients (3.7%) 
were HIV-negative and in one patient the HIV status was 
unknown. This finding correlates with the literature and is 
what we expected due to the high HIV infection prevalence 
in South Africa. There were 38 (74.5%) patients on ART at 
the time of diagnosis. However, the duration of treatment was 
unfortunately unknown. The median CD4 count at presenta-
tion was 232.5 cells/μL (range: 2–883 cells/μL) with most 
of the patients (71%) with a CD4 count <350 cells/μL. The 
VL was undetectable (<20 or <40 HIV-1 RNA copies/μL 
according to the assay used) in 58% of patients who had their 
VL measured around the time of diagnosis. The median CD4 
count was comparable with other studies (the range median 
CD4 count: 174–275 cells/μL). The percentage of patients 
with an undetectable VL at diagnosis (58%) was higher than 
other studies conducted in France, UK, or Australia. In these 
countries, studies reported undetectable HIV-1 RNA in 26%, 
44%, and 45.5% of the patients on ARTs, respectively.18,19 
However, the limits of detection of HIV-1 RNA and the way 
of reporting the results were different among the studies. Our 
study showed that most of the patients with CD had a CD4 
count <350 cells/μL. Still, the range of the CD4 count was 
significantly wide (2–883 cells/μL). Furthermore, we can 
conclude from our results that the suppression of the HIV 
VL below detectable limits does not prevent the development 
of MCD. On the contrary, it may contribute to an increased 
incidence of HIV-associated MCD.
The pathology reports for the diagnosis of CD were 
made on lymph node tissues in 53 patients, whereas in one 
patient the diagnosis was made on a splenic biopsy. The 
Figure 4 hhV8 status of the patients included in the study.
Abbreviation: hhV, human herpesvirus.
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histological variant was not reported in 31.5% of the cases. 
In HIV-associated MCD, PCV was the most frequently 
reported variant (57%), whereas MV was reported in 23% 
of the cases, HVV in 17%, and plasmablastic variant in 3% 
of the patients. PCV and MV constitute 80% of the variants 
reported in HIV-associated MCD. The coexistence of KS 
was reported in 24.1% of the cases. When compared with 
the group of cases with only CD histology, we report that 
the coexistence of KS is associated with a younger age at 
presentation, lower platelet counts, and a CD4 count of <200 
cells/μL. These findings were expected as KS is an AIDS-
defining illness. In our study, HHV8 (LANA-1) IHC stain 
was requested and reported in all cases except two cases 
diagnosed with CD in 2010. This staining was positive in 
scattered plasmablasts in mantle zones in 49/52 (94.2%) of 
the tissues examined (HHV8-associated CD) and was nega-
tive in 3/52 (5.8%) cases. In one case, HHV8 IHC stain was 
positive in scattered cells and there was a focal collection of 
HHV8-positive plasmablastic cells almost forming a sheet, 
with no light chain restriction. The EBER-ISH was positive 
in scattered cells with the histologic features of CD observed 
on H&E. These findings were interpreted as plasmablastic 
variant of MCD. Thirty-one patients who were diagnosed 
with CD had bone marrow biopsy procedures performed 
(30 HIV-positive and one HIV-negative). The bone marrow 
biopsy indications were to investigate causes of cytopenia(s) 
and to exclude marrow infiltration by infections or malignan-
cies. We reviewed all the 31 bone marrow biopsy reports and 
found that an increase in plasma cells in the bone marrow 
biopsies as well as bone marrow hypercellularity was the 
most prominent feature. Plasmocytosis was found in 80.6% 
of the bone marrow biopsies. The plasma cell percentages 
in the bone marrow were variable with range from 6% to 
70% of nucleated cells and commonly had an interstitial or 
perivascular distribution and rarely a diffuse distribution. The 
plasma cells were polytypic in all cases.
CD-like follicles were detected in 5/31 (16.1%) of the 
cases. Two cases showed typical CD-like follicles with germi-
nal center and mantle zones consisting of small lymphocytes 
arranged in concentric layers. The other three cases showed 
large lymphoid aggregates with vague concentric layers of 
lymphocytes and increased vascularity suggestive of CD 
infiltration of the bone marrow.
HHV8 (LANA-1) IHC stain was requested in 10 cases 
where five bone marrow biopsies had CD-like follicles, while 
the other five cases were without CD-like follicles. We found 
that HHV8 was detected in 2/10 (20%) cases with CD-like 
follicles. In our series, the rate of requesting HHV8 IHC and 
detection of HHV8-positive mononuclear cells were lower 
than what has been reported in other studies, which showed 
higher rate of detecting HHV8-positive mononuclear cells 
in the bone marrow (50%–80%) of the cases (38, 40). This 
indicates the need to request HHV8 on all patients with sus-
pected CD even if the typical features are not noted. In this 
series, we detected CD-like follicles in 5/31 (16.1%) of the 
bone marrow biopsies, which is comparable with the study 
published by Bacon et al that found CD-like follicles in 3/13 
(23.1%) of the cases.22–24
Conclusion
CD is a rare condition. However, in the setting with an 
increasing prevalence of HIV infection, as is the case of 
South Africa, we report a parallel and significant increase 
in the incidence of HIV-associated MCD in the last decade. 
This change is likely due to the continuous change in ART 
therapy protocols in South Africa since 2004 when ART was 
made available in the public hospitals. This means that we are 
now going to see more CD cases and therefore need to cre-
ate more awareness about this disease in our setting. Finally, 
our findings also highlight the need for HIV-related cancer 
registries in South Africa and Africa as a whole.
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Supplementary materials
Figure S1 Bar graph depicts number of patients and their hiV status diagnosed at Tah from 2007-2017
Abbreviations: CD, Castleman’s disease; Tah, Tygerberg academic hospital.
Figure S2 Chart shows trend of incidence of diagnosis of Castleman disease at Tah over a period of ten years.
Abbreviations: CD, Castleman’s disease; Tah, Tygerberg academic hospital.
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Figure S3 histogram showing age (years) distributions of patients with Castleman disease.
Figure S4 Bar graph depicts number CD patients were diagnosed at Tah by the age group and gender.
Abbreviations: CD, Castleman’s disease; Tah, Tygerberg academic hospital.
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Figure S5 Chart showing frequency of FBC abnormalities for patients at diagnosis.
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